Back to Journals » OncoTargets and Therapy » Volume 10

Polygonatum odoratum lectin promotes BECN1 expression and induces autophagy in malignant melanoma by regulation of miR1290

Authors Luan W, Qian Y, Ni X, Chanda TK, Xia Y, Wang J, Yan Y, Xu B

Received 27 July 2017

Accepted for publication 17 August 2017

Published 14 September 2017 Volume 2017:10 Pages 4569—4577


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Yao Dai

Wenkang Luan,1,* Yao Qian,2,* Xin Ni,3,* Tonmoy Kumar Chanda,1 Yun Xia,1 Jinlong Wang,1 Yulan Yan,4 Bin Xu1

1Department of Plastic Surgery, 2Department of Neurosurgery, 3Department of Gastroenterology, 4Department of Respiratory Medicine, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, China

*These authors contributed equally to this work

Abstract: Autophagy is not only a survival response to growth-factor or nutrient deprivation but also an important mechanism for tumor-cell suicide, including melanoma. Polygonatum odoratum lectin (POL) displays apoptosis- and autophagy-inducing effects in many human tumors. POL also inhibits the growth of melanoma cells, but its role and molecular mechanism in malignant melanoma remain unclear. In this study, we found that POL suppressed proliferation and induced autophagy in melanoma cells. miR1290 was upregulated and inhibited autophagy in melanoma. BECN1 is the direct functional effector of miR1290. Furthermore, we found that POL promoted BECN1 expression though inhibition of miR1290, thus inducing melanoma-cell autophagy. This finding elucidates a new role and mechanism for POL in melanoma, and provides a potential antineoplastic agent for melanoma treatment.

Keywords: autophagy, Polygonatum odoratum lectin, miR1290, BECN1, melanoma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]